The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a significant regulatory setback threatening biotech revenues, a European Medicines Agency (EMA) committee recommended revoking marketing authorization for Amgen's drug Tavneos (avacopan), according to a Wall Street Journal report. The recommendation bars initiating new patients and urges switching existing patients to suitable alternatives, dealing a heavy blow to Amgen's rare-disease portfolio.
Sign in to access this content
Sign InTavneos is indicated for ANCA-associated vasculitis, a niche immunology market. While the specific reasons are undisclosed, EMA committees typically act on safety or efficacy data. This decision comes amid heightened regulatory scrutiny of biopharma in Europe. Per market data, Amgen shares closed at $352.82 on June 25, retreating from an intraday high of $359.10.
Investors await Amgen's response, which may include legal challenges or a re-examination request. Technically, the range between $350.06 low and $359.10 high (June 25 close) defines near-term support and resistance. Markets will also watch the EMA's final ruling and any knock-on effects on Amgen's pipeline products.